Company profile: Diagnostic Hybrids
1.1 - Company Overview
Company description
- Provider of cellular and molecular diagnostic kits and systems for detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. Offers the D3 FastPoint L-DFA influenza A/B identification kit; Vitros Integrated, Chemistry, and Immunoassay Systems with broad, waterless testing menus; Ortho Vision Swift analyzer for automated donor typing; and Lyra real-time PCR assays that simplify sample processing.
Products and services
- Vitros Integrated Systems: Delivers comprehensive chemistry and immunoassay menus, enabling diverse tests on a single platform, with plumbing-free operation that eliminates water maintenance requirements
- Vitros Immunoassay Systems: Streamlines laboratory workflows via integrated reagent packs and intelligent technologies, delivering a broad menu of up to 120 assays for donor screening and infectious disease testing
- Vitros Chemistry Systems: Produces routine and specialty chemistry diagnostic testing, enhancing lab productivity with a broad testing menu and waterless operation that avoids plumbing requirements
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diagnostic Hybrids
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
MedMira
HQ: Canada
Website
- Description: Provider of rapid diagnostics, including FDA-approved Reveal G4 for instant HIV results using Rapid Vertical Flow Technology; Multiplo Multiplex Tests for simultaneous detection of HIV-1/2, hepatitis B and C, and syphilis; Reveal HIV; Multiplo TP/HIV; Multiplo HBc/HIV/HCV; and the Miriad RVF Toolkit for developing and commercializing rapid tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedMira company profile →
Discuva
HQ: United Kingdom
Website
- Description: Provider of next-generation antibiotic discovery, Cambridge (UK)-based, established to address major gaps in the treatment of infective disease using proprietary methods, and developer of Ivonescimab (SMT112), a bispecific PD-1/VEGF antibody for oncology in Phase III trials for non-small cell lung cancer and other solid tumors, with over 1,600 patients treated.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Discuva company profile →
NanoCures
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology and infectious disease immunity platforms, including: Cures Platform targeting specific genomic and molecular pathways to yield multiple therapeutics; Data/AI Platform using biometric, genomic, molecular, and environmental data with AI/ML to detect diseases early and guide new cure development; and Developer Platform offering resources, data, and tools to lower barriers and encourage innovation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCures company profile →
Leyden Labs
HQ: The Netherlands
Website
- Description: Provider of a mucosal immunity platform targeting commonalities of viral families to protect against known and future respiratory viruses, offering intranasal antibody sprays for immediate antiviral protection, including PanFlu nasal spray (CR9114 antibody) for broad influenza protection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Leyden Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diagnostic Hybrids
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diagnostic Hybrids
2.2 - Growth funds investing in similar companies to Diagnostic Hybrids
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diagnostic Hybrids
4.2 - Public trading comparable groups for Diagnostic Hybrids
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →